JP7100019B2 - 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する - Google Patents

選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する Download PDF

Info

Publication number
JP7100019B2
JP7100019B2 JP2019508935A JP2019508935A JP7100019B2 JP 7100019 B2 JP7100019 B2 JP 7100019B2 JP 2019508935 A JP2019508935 A JP 2019508935A JP 2019508935 A JP2019508935 A JP 2019508935A JP 7100019 B2 JP7100019 B2 JP 7100019B2
Authority
JP
Japan
Prior art keywords
tamoxifen
serm
subject
retinal
photoreceptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019508935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532026A5 (enExample
JP2019532026A (ja
Inventor
ワイ ティー． ウォン，
シュウ ワン，
リアン ジャオ，
ウェンシン マ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2019532026A publication Critical patent/JP2019532026A/ja
Publication of JP2019532026A5 publication Critical patent/JP2019532026A5/ja
Application granted granted Critical
Publication of JP7100019B2 publication Critical patent/JP7100019B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/398—Electrooculography [EOG], e.g. detecting nystagmus; Electroretinography [ERG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
JP2019508935A 2016-08-19 2017-08-10 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する Active JP7100019B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377439P 2016-08-19 2016-08-19
US62/377,439 2016-08-19
PCT/US2017/046359 WO2018034945A1 (en) 2016-08-19 2017-08-10 Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration

Publications (3)

Publication Number Publication Date
JP2019532026A JP2019532026A (ja) 2019-11-07
JP2019532026A5 JP2019532026A5 (enExample) 2020-08-13
JP7100019B2 true JP7100019B2 (ja) 2022-07-12

Family

ID=59702849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508935A Active JP7100019B2 (ja) 2016-08-19 2017-08-10 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する

Country Status (5)

Country Link
US (1) US11040019B2 (enExample)
EP (1) EP3484463B1 (enExample)
JP (1) JP7100019B2 (enExample)
AU (1) AU2017312499B2 (enExample)
WO (1) WO2018034945A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12357592B2 (en) * 2018-01-25 2025-07-15 Per Hall Compositions and methods for monitoring the treatment of breast disorders
CN108295055B (zh) * 2018-02-26 2019-11-05 王晓琳 他莫昔芬在制备保护视网膜感光细胞的药物中的应用
JP2020174859A (ja) * 2019-04-17 2020-10-29 学校法人日本医科大学 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法
JP7392219B2 (ja) * 2020-01-20 2023-12-06 株式会社萌芽プランツ フラボノイド組成物
GB202000926D0 (en) * 2020-01-22 2020-03-04 Ucl Business Ltd Method of diagnosis
KR20230003483A (ko) * 2020-03-26 2023-01-06 다이아멘티스 인크. 망막 신호 데이터를 처리하고 병태들을 식별하기 위한 시스템들 및 방법들

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001511182A (ja) 1997-02-09 2001-08-07 ファーモス コーポレイション ステロイドホルモンの永久に荷電された誘導体の増進された抗血管形成誘導活性
WO2006040839A1 (ja) 2004-10-15 2006-04-20 Advanced Medicine Research Institute 眼疾患処置用点眼剤及びキット
JP2013528626A (ja) 2010-06-16 2013-07-11 アンドルシェルシュ・インコーポレイテッド エストロゲン関連疾患を治療するまたは予防するための方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (enExample) 1962-09-13
FR2558373B1 (fr) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US4852579A (en) 1987-04-20 1989-08-01 Karl Storz Endoscopy Gmbh And Company Photocharacterization and treatment of normal abnormal and ectopic endometrium
JP2918991B2 (ja) 1990-05-25 1999-07-12 三菱瓦斯化学株式会社 漂白洗浄剤組成物
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
DE19718826A1 (de) 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
JP4837861B2 (ja) 1999-10-21 2011-12-14 アルコン，インコーポレイティド ドラッグデリバリ製剤
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AU2001271163A1 (en) 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
EP1335727B1 (en) 2000-10-25 2004-10-06 Eli Lilly And Company Method for inhibiting cataracts
ES2250504T3 (es) 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.
US20030032676A1 (en) 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
EP1952809B1 (en) 2002-12-18 2017-08-02 Besins Healthcare Luxembourg SARL Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen
US20050244461A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
ATE439123T1 (de) 2004-07-02 2009-08-15 Novagali Pharma Sa Verwendung von emulsionen zur intra- und periocularen injection
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
CN102351732B (zh) 2005-11-28 2014-10-29 Gtx公司 核受体结合剂
US20130338145A1 (en) 2006-10-03 2013-12-19 Claire H. Mitchell Method for Mediating Dopamine Receptor-Driven Reacidification of Lysosomal pH
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2011113904A1 (en) * 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
EP2554662A1 (en) * 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
CN103211803A (zh) 2013-04-02 2013-07-24 苏州大学附属第一医院 他莫昔芬在治疗蛛网膜下腔出血后发生的早期脑损伤的应用
EP2989110B1 (en) 2013-04-24 2018-08-08 Smart Brain s.r.o. Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
WO2016064959A1 (en) 2014-10-21 2016-04-28 Odin Biotech Two-layer ocular implant comprising a tyrosine kinase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001511182A (ja) 1997-02-09 2001-08-07 ファーモス コーポレイション ステロイドホルモンの永久に荷電された誘導体の増進された抗血管形成誘導活性
WO2006040839A1 (ja) 2004-10-15 2006-04-20 Advanced Medicine Research Institute 眼疾患処置用点眼剤及びキット
JP2013528626A (ja) 2010-06-16 2013-07-11 アンドルシェルシュ・インコーポレイテッド エストロゲン関連疾患を治療するまたは予防するための方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS，2011年，Vol. 27, No. 3，pp. 225-233
The Journal of Clinical Investigation，2015年，Vol. 125, No. 9，pp. 3704-3713
The Journal of Neuroscience，2016年03月02日，Vol. 36, No. 9，pp. 2827-2842

Also Published As

Publication number Publication date
JP2019532026A (ja) 2019-11-07
US20190209497A1 (en) 2019-07-11
CA3032153A1 (en) 2018-02-22
WO2018034945A1 (en) 2018-02-22
EP3484463B1 (en) 2020-02-12
EP3484463A1 (en) 2019-05-22
AU2017312499B2 (en) 2023-02-02
US11040019B2 (en) 2021-06-22
AU2017312499A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
JP7100019B2 (ja) 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する
AU2023251388B2 (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
US12357565B2 (en) Ocular implant containing a tyrosine kinase inhibitor
US11865123B2 (en) Methods of inhibiting pathological angiogenesis
EA006746B1 (ru) Способы лечения глазных неоваскулярных заболеваний
US20040213782A1 (en) Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
US20110189174A1 (en) Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
KR20190134588A (ko) 다중 키나아제 억제제 및 안구 섬유증에의 사용
MXPA05000773A (es) Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad.
WO2011097577A2 (en) Compositions and methods for treating or preventing retinal degeneration
JP2018506519A (ja) 緑内障を治療するための組成物及び方法
JP2009519962A (ja) 眼投与用局所メカミルアミン製剤およびその使用
JP7615139B2 (ja) 萎縮型加齢黄斑変性（ａｍｄ）又は萎縮型ａｍｄに続発する地図状委縮の治療用抗ｃ５剤
JP2021512847A (ja) キレート剤、浸透促進剤およびヒドロキシエチルセルロースを含む眼科疾患治療用製剤
JP2013544838A (ja) 網膜の疾患を治療するための方法
CA3032153C (en) Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
RU2815482C2 (ru) Лечение глазных болезней типа дегенерации желтого пятна, глаукомы и диабетической ретинопатии с помощью лекарственных средств, устраняющих стареющие клетки
WO2023229993A1 (en) Ophthalmic formulation capable of delivering metformin to choroid rpe and retina
CA3222168A1 (en) Trpa1 channel antagonist compound for use in degenerative retinal diseases
HK40032714A (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
Thakur Retinal delivery of steroidal and non-steroidal drugs for the treatment of back of the eye disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200703

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220509

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220517

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220630

R150 Certificate of patent or registration of utility model

Ref document number: 7100019

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250